Calcium
Active ingredient
- Drug class
- -
- Availability
- Over-the-counter
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 6
- FDA reports (12 mo)
- 28,367
Overview
Calcium is an active pharmaceutical ingredient. The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 4 | April 17, 2026 |
| US United States | FDA | 1 | January 23, 2024 |
| CA Canada | Health Canada | 1 | March 22, 2025 |
GBUnited Kingdom· MHRA
4 products
Uses
Leucovorin (folinic acid) is the formyl derivative of tetrahydrofolic acid which is a metabolite and active form of folic acid. g. Methotrexate. g. methotrexate, to minimise systemic toxicity. c) The treatment of megaloblastic anaemias due to sprue, nutritional deficiency, pregnancy, infancy, liver disease and malabsorption syndrome.
How to take
USUnited States· FDA
1 product
Uses
INDICATION & USAGE SECTION take two capsules once, two times a day
How to take
CACanada· Health Canada
1 product
Uses
AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 4 WARNINGS AND PRECAUTIONS .........................................................................................
5 ADVERSE REACTIONS........................................................................................................... 7 DRUG INTERACTIONS .........................................................................................................
10 DOSAGE AND ADMINISTRATION ..................................................................................... 13 OVERDOSAGE .......................................................................................................................
15 ACTION AND CLINICAL PHARMACOLOGY ................................................................... 15 STORAGE AND STABILITY ................................................................................................. 19 DOSAGE FORMS, COMPOSITION AND PACKAGING ....................................................
Sources & citations
- [1]MHRA (UK) · PL045150017 · revised January 2, 2026
- [2]FDA DailyMed · 11df7d66-7e85-d3… · revised January 23, 2024 [PDF]
- [3]Health Canada (DPD) · 02362414 · revised March 22, 2025
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.